Preview Newsletter

XARELTO Media Monitoring – Week of 10-9-15

Plaintiff Attorney Press Releases

Xarelto Lawsuit Update: Lawsuits Allege that Drug was Improperly Marketed
Oct 2, 2015 | Digital Journal
By Marc Goldich

BloodThinnerHelp.com reports on allegations made by current Xarelto lawsuits. Many of the lawsuits filed in the Xarelto multidistrict litigation, MDL, allege that Xarelto was marketed by its manufacturers as a safer alternative to other blood thinner drugs while in reality this was not true. For more detailed information on the Xarelto lawsuits, click here.
Xarelto Lawsuit Update: New Developments in Phila. Mass Tort Litigation
Oct 6, 2015 | Fox Carolina
By Marc Goldich

BloodThinnerHelp.com reports today on two new developments in the Philadelphia Mass Tort Litigation. Recently, two new case management orders, Case Management Order No. 5 and Case Management Order No. 6, were released. Case Management Order No. 5 is a stipulated protective order which outlines how certain documents including emails, text messages, and instant messages, should be protected throughout the litigation process. This order was released on May 19, 2015.
Xarelto Lawsuit: The Alleged Side Effects And Risks
Oct 7, 2015 | KCEN-TV
By Marc Goldich

BloodThinnerHelp.com reports on the serious side effects and risks allegedly associated with Xarelto. Xarelto is an Xa inhibitor and blood thinner that is prescribed to millions of people across the nation to help prevent blood clots and strokes. It is frequently used to treat atrial fibrillation, or after knee and hip replacement surgeries.
Xarelto Lawsuit: The Similarities Of Litigation With Pradaxa
Oct 8, 2015 | WAND-TV
By Marc Goldich

BloodThinnerHelp.com reports on similarities noted in current Xarelto lawsuits and prior Pradaxa lawsuits. Pradaxa, like Xarelto, is one of several new versions of blood thinners. This version, sold by Boehringer Ingelheim, recently settled around 4,000 lawsuits which claimed that the drug had induced episodes of serious, uncontrollable bleeding. In order to settle these claims, Boehringer Ingelheim paid about $650 million.
Ross Feller Casey Files Nation's First Xarelto Lawsuit Alleging Once-A-Day Dosage Led To Stroke
Oct 9, 2015 | PR Newswire
By Ross Feller Casey, LLP

Following months of investigation, Ross Feller Casey, LLP has filed the first lawsuit in the nation alleging that the anticoagulant Xarelto's recommended dosage doesn't work for as long as promised, sometimes with life-threatening results. The firm filed a lawsuit today in state court in Philadelphia on behalf of a Florida man who suffered an ischemic stroke because the drug didn't work as the manufacturer suggested. Ross Feller Casey is preparing to file numerous other suits shortly on behalf of clients from across the country with similar claims.
Xarelto Lawsuit Update: New Wrongful Death Lawsuit Filed Against Xarelto Manufacturers
Oct 9, 2015 | GTN News
By Marc Goldich

BloodThinnerHelp.com reports today on one of the latest lawsuits filed in the Xarelto multidistrict litigation, or MDL. This new federal lawsuit was filed by the son of a deceased Georgia man who passed away from complications due to internal bleeding. The lawsuit was filed on March 20, 2015 against the manufacturers of Xarelto, Bayer AG and Janssen Pharmaceuticals, a subdivision of Johnson&Johnson. The son, a Tennessee resident, alleges in the lawsuit that his father died from an uncontrollable internal bleeding incident which he believes was caused by his father’s Xarelto usage. This case is filed in the Xarelto MDL in the United States District Court for the Eastern District of Louisiana and is filed under case number 2:15-cv-00886.

Plaintiff Attorney Blogs

Son Blames Xarelto for Father’s Death, Seeks Punitive Damages
Oct 2, 2015 | The Legal Examiner
By Eric T. Chaffin

In December 2014, the U.S. Judicial Panel on Multidistrict Litigation (JPML) consolidated all federal Xarelto lawsuits into one court in the Eastern District of Louisiana before the Honorable Judge Fallon. Currently, about 400 cases are pending there. One of the cases recently filed involves a plaintiff who claims the anticoagulant blood caused internal bleeding that led to the death of his father.
Xarelto Bleeding Lawsuit Alleges Ohio Man Bled to Death
Oct 2, 2015 | Top Class Actions
By Ashley Vanover

The controversial blood thinning drug Xarelto has been named in yet another lawsuit – this time following the death of an Ohio resident who was prescribed the medication in July 2013. Plaintiff Judy C., filing on behalf of her deceased spouse, commenced her Xarelto wrongful death lawsuit on Sept. 15 in Louisiana federal court, home of the ongoing Xarelto MDL to address the alleged widespread injuries caused by the new generation anticoagulant.
Bellwether Trials Scheduled for Xarelto Coordinated Litigation
Oct 2, 2015 | Drug Reporter
By Whitney Taylor

Four bellwether trials have been scheduled in the ongoing coordinated proceedings underway involving the blood-thinning medication Xarelto. The judge overseeing the coordination has put four trials on the calendar in the first half of 2017, which will provide valuable insight into how subsequent Xarelto lawsuits may be resolved.
The Truth About The Blood Thinner And The Side Effects Of Xarelto
Oct 3, 2015 | Xarelto Settlement Lawyers

Have you taken Xarelto and now you are wondering if you have suffered any side effects from it? Maybe you are wondering what the side effects of Xarelto are. If you are curious about the side effects of xarelto , then continue to read the rest of this article, as some of the side effects will be discussed below.
So What is the Xarelto Lawsuit About?
Oct 4, 2015 | Legal Guardianship

They say taking street drugs can kill you. Well, that is obviously true. You see it in the news every single day. However, another news story that is becoming quite popular is prescription drugs causing serious harm and in some cases killing people. It is not the thing you would expect to happen when your doctor writes you a prescription to treat something you might be suffering from or at risk for. The Xarelto lawsuit is an example. It is alleged that the drug is responsible for causing major bleeding events in some people who take it. The drug is intended to save lives. It is supposed to stop dangerous blood clots that can cause strokes from forming.
Doctors Waiting On Real-World Safety Data From New Blood Thinners
Oct 4, 2015 | Righting Injustice
By Jennifer Walker-Journey

Drugs from a new class of blood thinners are gaining traction in sales, but analysts say they have a lot to prove before doctors push aside the long-used warfarin for the new drugs.
Xarelto and the FDA: An Uneasy Relationship
Oct 3, 2015 | Baron and Budd

Since the U.S. Food and Drug Administration (FDA) first approved Xarelto for use in 2011 after hip or knee surgeries, the drug has been placed under intense scrutiny by the agency. Even though the FDA granted approval for the medication to prevent pulmonary embolism (blood clots in the lung) and deep vein thrombosis after hip and knee procedures, the agency had serious concerns about the protocols used in conducting certain clinical studies. Over the years, the FDA has had some reservations regarding Xarelto. Here are a few examples.
Xarelto Uncontrollable Bleeding Trials Set for 2017
Oct 5, 2015 | The Legal Examiner
By Shezad Malik MD JD

Since December 2014, all federal product liability lawsuits filed against Bayer and Johnson & Johnson over the bleeding side effects of Xarelto have been centralized and consolidated before U.S. District Judge Eldon Fallon in the Eastern District of Louisiana as part of an MDL, or multidistrict litigation.
Xarelto Side Effects Lawsuit Filed for Wrongful Death
Oct 5, 2015 | American Injury Attorney Group

A Xarelto side effects lawsuit has been filed by a man who alleges that the blood thinner caused the wrongful death of his father. The lawsuit was filed two years after the plaintiff’s father died from a major internal bleed, Xarelto lawyers note. If you or a loved one took Xarelto and suffered complications, contact the American Injury Attorney Group today to learn more about your options. We can answer your questions in a free, confidential, no-obligation consultation, and if you wish to pursue a claim, we can connect you with an affiliated Xarelto lawsuit attorney.
Ohio Woman Files Xarelto Gastro-Intestinal Bleeding Injury Lawsuit
Oct 6, 2015 | The Legal Examiner
By Shezad Malik MD JD

Molly Harr, from Ohio, has filed a personal injury and product liability lawsuit claiming that Xarelto side effects caused her to develop gastrointestinal bleeding, after using the oral blood thinner or anticoagulant for chronic atrial fibrillation.
Four Plaintiffs File Joint Complaint in Xarelto MDL
Oct 6, 2015 | Injury Lawyer News
By Sarah May

Adding to the growing list of lawsuits in the Xarelto federal multidistrict litigation (MDL), a group of four plaintiffs have come together to file a joint complaint alleging that they each suffered serious harm after using Jannsen’s anticoagulant drug. The highly detailed complaint outlines the history of Xarelto, how it came to market and the reasons why plaintiffs believe its manufacturer negligently placed the general public at serious, unnecessary risk of severe complications such as those they experienced.
Xarelto Lawsuit Update: Recent Lawsuit Filed By New York Plaintiff
Oct 7, 2015 | The Legal Herald
By Marc Goldich

Federal internal bleeding lawsuits are filed against the manufacturers of Xarelto, alleging the drug can cause serious, uncontrollable internal bleeding. A Texas woman has recently filed a lawsuit in New York state against the manufacturers of the anticoagulant drug Xarelto, Bayer AG and Janssen Pharmaceuticals, a subdivision of Johnson&Johnson.
Xarelto Gastrointestinal Bleeding Followed Use for Atrial Fibrillation, Lawsuit Alleges
Oct 8, 2015 | AboutLawsuits.com
By Irvin Jackson

An Ohio woman has filed a product liability lawsuit alleging that side effects of Xarelto caused her to suffer gastrointestinal bleeding and other problems, after using the novel oral anticoagulant for chronic atrial fibrillation. The complaint (PDF) was brought in the U.S. District Court for the Southern District of Ohio on October 5, on behalf of Molly Ann Harr and her husband, Daniel Harr, Jr.
Xarelto Bellwether Trials Set
Oct 8, 2015 | Drug Lawsuit Source

In previous months, lawsuits against the Johnson & Johnson and Bayer AG’s popular blood thinner, Xarelto, have continued to rise dramatically. In response to the increasing number of plaintiffs bringing cases alleging injuries as the result of being prescribed and taking Xarelto, several bellwether trials have been scheduled to take place in the United States within the next year and a half to two years.
New Xarelto Lawsuits Filed in 2015
Oct 8, 2015 | Xarelto Problems

21 cases from 10 districts over the blood-thinning drug Xarelto were consolidated into a multidistrict litigation (“MDL”) for pretrial proceedings before Judge Fallon in New Orleans. Meanwhile, more Xarelto lawsuits continue to mount, with 86 suits pending, according to the Judicial Panel on Multidistrict Litigation’s January 15, 2015 monthly report. All contend that the anticoagulant manufactured and marketed to safely and effectively clot blood has failed to do so, causing uncontrolled, sometimes fatal, bleeding.
Is Xarelto Linked with an Increased Risk of Liver Injury?
Oct 8, 2015 | The Legal Examiner
By Kendra Goldhirsch

Health Canada has completed a safety review of Xarelto (rivaroxaban), a newer-generation anti-coagulant medication manufactured by Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson).
Atrial Fibrillation Patient Files Xarelto Bleeding Lawsuit
Oct 9, 2015 | Top Class Actions
By Paul Tassin

An atrial fibrillation patient filed a Xarelto bleeding lawsuit, alleging the drug caused dangerous gastrointestinal bleeding. Plaintiff Lloyd E. says he started taking Xarelto in May 2014 on his doctor’s advice as a treatment for atrial fibrillation and coronary artery disease. A few months later, he says, he developed an acute gastrointestinal bleed for which he had to be hospitalized.

Plaintiff Attorney Press Releases

Xarelto Lawsuit Update: Lawsuits Allege that Drug was Improperly Marketed

Oct 2, 2015 | Digital Journal

By Marc Goldich

BloodThinnerHelp.com reports on allegations made by current Xarelto lawsuits. Many of the lawsuits filed in the Xarelto multidistrict litigation, MDL, allege that Xarelto was marketed by its manufacturers as a safer alternative to other blood thinner drugs while in reality this was not true. For more detailed information on the Xarelto lawsuits, click here.
Xarelto was released onto the United States market in 2011 after receiving approval from the Food and Drug Administration, FDA, to treat atrial fibrillation, deep vein thrombosis, and to be used in patients who have recently undergone a hip or knee replacement surgery. After the drug was released onto the market, Xarelto’s manufacturers, Bayer AG and Janssen Pharmaceuticals, the pharmaceutical subdivision of Johnson&Johnson, began a very intense marketing campaign to market Xarelto to the public. Television commercials featuring popular athletes and well known public figures were aired and advertisements were placed in popular and well regarded medical journals. These advertisements touted the convenience of Xarelto, discussing Xarelto’s lack of blood monitoring, one size fits all dosing method, and stating that Xarelto does not require a restrictive diet.
Xarelto Lawsuits Allege Drug is Dangerous:
Xarelto is different from other blood thinners because it is part of a new class of drugs called Xa inhibitors. Xa inhibitors work by blocking the chemical in the blood that is responsible for making the blood clot, thrombin. By blocking thrombin, Xarelto leaves the blood with no way to clot. This is especially dangerous because there is no antidote for the anticoagulant effects of Xarelto, so if a patient experiences an internal bleed, there is no way to stop the blood short of extreme lifesaving measures. This is in sharp contrast to the situation a patient is in if they experience an internal bleed and are taking the traditional blood thinner Warfarin. If a patient bleeds internally while on Warfarin, a doctor can administer vitamin K and the blood will clot again. The lawsuits allege that Xarelto’s manufacturers were aware of this information and put the drug to market anyway. They also allege that the manufacturers failed to adequately inform patients and doctors about the true dangers of Xarelto usage.
“If the manufacturers of Xarelto did indeed know about the dangers of the drug, they deserve to be brought to justice.” Xarelto attorney Marc Goldich said, “We strongly encourage anybody who feels that they have been harmed from Xarelto to contact us immediately.”
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
http://www.digitaljournal.com/pr/2695271

Return to headline | Return to top
Xarelto Lawsuit Update: New Developments in Phila. Mass Tort Litigation

Oct 6, 2015 | Fox Carolina

By Marc Goldich

October 06, 2015 – /PressAdvantage/ – BloodThinnerHelp.com reports today on two new developments in the Philadelphia Mass Tort Litigation. Recently, two new case management orders, Case Management Order No. 5 and Case Management Order No. 6, were released.
Case Management Order No. 5 is a stipulated protective order which outlines how certain documents including emails, text messages, and instant messages, should be protected throughout the litigation process. This order was released on May 19, 2015.
Case Management Order No. 6 orders that the temporary discovery stay that was outlined in case management order 1 on February 10 2015 is to be lifted and both parties should proceed with the discovery process as Case Management Order no. 6 dictates. This order was released on July 7, 2015.
Xarelto Victims Filing Lawsuits:
The Philadelphia Mass Tort litigation was established after a motion was made to consolidate the rising number of lawsuits that made similar allegations against the same defendants, in this case, the manufacturers of Xarelto, pharmaceutical conglomerates Bayer AG and Janssen Pharmaceuticals, a subdivision of Johnson&Johnson. There are about 400 cases currently consolidated in this mass tort group and the number is expected to continue to rise as the pretrial litigation continues. Consolidating these cases in a mass tort litigation will expedite the judicial process for all parties involved and save on judicial resources. A mass tort group is different from a class action because although these cases are consolidated, they are still tried as individual cases.
Most of the lawsuits filed commonly allege that Xarelto usage has caused either themselves or a loved one severe, uncontrollable internal bleeding which has led to serious injury. The lawsuits also allege that the manufacturers of Xarelto were aware of the true dangers that Xarelto presented and failed to adequately warn doctors and patients of these dangers.
Xarelto’s Dangerous Defect:
The lawsuits allege that the reason that Xarelto is especially dangerous is because the drug does not have a corresponding antidote to its anticoagulant effects. This is different from the way that traditional blood thinners work, such as Warfarin. If a patient taking Warfarin experiences an internal bleeding emergency, a doctor can administer vitamin K and the blood will clot again. If a patient taking Xarelto experiences an internal bleeding emergency, there is no way to stop the bleeding short of extreme life-saving medical measures.
“If the manufacturers of Xarelto were aware of the drug’s defects and put it to market anyway, they deserve to be brought to justice.” Xarelto attorney Marc Goldich said, “We strongly encourage anybody who feels they have been harmed by Xarelto usage to contact us immediately.”
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
http://www.foxcarolina.com/story/30199909/xarelto-lawsuit-update-new-developments-in-phila-mass-tort-litigation#ixzz3o0KjG7oU

Return to headline | Return to top
Xarelto Lawsuit: The Alleged Side Effects And Risks

Oct 7, 2015 | KCEN-TV

By Marc Goldich

BloodThinnerHelp.com reports on the serious side effects and risks allegedly associated with Xarelto. Xarelto is an Xa inhibitor and blood thinner that is prescribed to millions of people across the nation to help prevent blood clots and strokes. It is frequently used to treat atrial fibrillation, or after knee and hip replacement surgeries.
Although all blood thinners come with risks, Xarelto has now been the focus of many FDA warnings and nation-wide lawsuits. In general, if the body’s blood is unable to clot and sustains even minor injuries during a fall, a person can experience internal bleeding and therefore dangerous health problems.
Internal bleeding commonly requires immediate hospitalization. Sadly, this can cause death. The alleged side effects noted by those bringing lawsuits against Xarelto manufacturers Bayer AG and Johnson and Johnson include this and several other dangerous conditions.
Gastrointestinal and abdominal bleeding is a noted side effect in several lawsuits, which can cause pools of blood to develop in some areas of the body while cutting off blood supply to other vital organs. Symptoms of this side effect can include coughing or vomiting up blood.
Brain bleeding, strokes, and brain hemorrhages are also alleged side effects experienced by those taking Xarelto. Brain bleeds commonly result in stroke, because the blood causes the brain to become starved of much-needed oxygen. This can cause brain damage as the cells of the brain begin to die, and can result in paralysis or death. Symptoms of this side effect include numbness in extremities, slurred speech, difficulty moving, headaches or vision trouble, and lack of coordination.
Additional side effects allegedly connected to Xarelto use are pulmonary embolism, which is when blood flow to the lungs becomes blocked. The most common form of this is deep vein thrombosis, and symptoms include shortness of breath, significant chest pain, or coughing up blood. Spinal bleeding, colon bleeding, and liver dysfunction have all also been noted as potential side effects of Xarelto in allegations as well.
According to the JAMA Internal Medicine Journal, both hepatitis and liver dysfunction can occur because of Xarelto. In December of 2014, the Food and Drug administration also warned about the risk of hepatitis associated with Xarelto.
Those who have experienced any of the above health issues after using Xarelto or a similar Xa inhibitor may be entitled to compensation. Xarelto attorneys are currently providing free consultations for anyone trying to explore their rights.
Marc Goldich, Esq. of Sheller P.C. said “I aim to represent families and individuals who may have suffered injuries or lost loved ones due to serious internal bleeding possibly caused by Xarelto use.”
Those looking for more information should contact Marc Goldich, Esq., call 877-635-5876 at their convenience.
http://www.kcentv.com/story/30208562/xarelto-lawsuit-the-alleged-side-effects-and-risks

Return to headline | Return to top
Xarelto Lawsuit: The Similarities Of Litigation With Pradaxa

Oct 8, 2015 | WAND-TV

By Marc Goldich

October 08, 2015 – /PressAdvantage/ – BloodThinnerHelp.comreports on similarities noted in current Xarelto lawsuits and prior Pradaxa lawsuits. Pradaxa, like Xarelto, is one of several new versions of blood thinners. This version, sold by Boehringer Ingelheim, recently settled around 4,000 lawsuits which claimed that the drug had induced episodes of serious, uncontrollable bleeding. In order to settle these claims, Boehringer Ingelheim paid about $650 million.
The Institute for Safe Medication Practices, a non-profit organization focused on medical product education for consumers and the community, issued a report which showed a higher number of serious adverse effects associated with Xarelto than Pradaxa. While it has been noted that these numbers could be a bit misleading because of prior negative publicity surrounding Pradaxa, (therefore initially increasing users of Xarelto and therefore adverse effects counted with Xarelto use,) the group determined that blood thinners, in general, are considered to be “high-risk treatment(s).”
As lawsuits surrounding Xarelto continue to grow, plaintiffs wonder if their litigation will end in a similar settlement to that seen with Pradaxa. Each blood thinner works similarly, and therefore carries with it many of the same potentially dangerous side effects. Although continued bleeding is a serious and commonly experienced complication with any anticoagulant-type drug, Xarelto has been deemed more dangerous than traditional blood thinners because it has no antidote available that can reverse its blood-thinning effects if need be.
Plaintiffs involved in federal Multidistrict litigation concerning Xarelto complications are seeking compensation for physical damages and pain and suffering incurred from Bayer, as well as Janssen Pharmaceuticals, (a division of Johnson & Johnson). Lawsuits allege that these manufacturers marketed the drug incorrectly, and that they continue to market it as if it is a safe anticoagulant option, despite the fact that doctors have no way of stopping its users from bleeding in an emergency. Complaints also allege that Xarelto users were not adequately warned about the health risks associated with the product, and many assert that they were victims of serious bleeding complications due to using the drug.
If you or someone you love have suffered serious bleeding or other connected health issues while using Xarelto, Marc Goldich, Esq. is ready to help you explore your rights. You may be entitled to a lawsuit and compensation.
“I have been diligently working on assisting the effort to ensure that everyone who is entitled to join the Xarelto litigation has that opportunity,” said Marc Goldich, Esq.
To obtain additional information on your rights or ask questions, contact attorney Marc Goldich today for a completely free, completely confidential evaluation and legal advice at 877-635-5876.
http://www.wandtv.com/story/30220484/xarelto-lawsuit-the-similarities-of-litigation-with-pradaxa

Return to headline | Return to top
Ross Feller Casey Files Nation's First Xarelto Lawsuit Alleging Once-A-Day Dosage Led To Stroke

Oct 9, 2015 | PR Newswire

By Ross Feller Casey, LLP

PHILADELPHIA, Oct. 8, 2015 /PRNewswire/ -- Following months of investigation, Ross Feller Casey, LLP has filed the first lawsuit in the nation alleging that the anticoagulant Xarelto's recommended dosage doesn't work for as long as promised, sometimes with life-threatening results.
The firm filed a lawsuit today in state court in Philadelphia on behalf of a Florida man who suffered an ischemic stroke because the drug didn't work as the manufacturer suggested. Ross Feller Casey is preparing to file numerous other suits shortly on behalf of clients from across the country with similar claims.
Xarelto, approved in 2011, has rapidly become a blockbuster drug, with more than $1.3 billion in U.S. sales in 2013. Those sales are due in large part to the drug's recommended once-a-day dosage, less than its competitors.
Xarelto (rivaroxaban) is manufactured and marketed in a partnership between Janssen Pharmaceuticals (a Johnson & Johnson subsidiary) and Bayer HealthCare. The drug has been linked to severe, uncontrollable bleeding events, and Ross Feller Casey has already filed more than 60 cases involving those injuries.
Unlike those cases, the suit filed today is believed to be the first in the country to allege that Xarelto does not prevent, and may actually have contributed to, ischemic strokes in clients suffering from atrial fibrillation. The case alleges that the indicated 20mg dose results in a lack of protection against stroke/systemic embolism for a substantial window of the day if the dose is given once-per-day.
Xarelto is the only new anticoagulant recommended by the manufacturer for once-per-day dosing in the clinical setting of non-valvular atrial fibrillation. All other comparable anticoagulants are dosed on a twice-per-day basis.
Mark Hoffman, M.D., an attorney with Ross Feller Casey, states "Xarelto's rapid half-life, which was touted by its manufacturer as an advantage over the older, yet more proven, warfarin therapy, as well as the drug's pharmacodynamic properties, often leaves a substantial portion of a patient's 24-hour period with no protection against clots whatsoever." Hoffman, who, with Brian McCormick, Jr., is handling these lawsuits for Ross Feller Casey, has recently been appointed to the Plaintiffs' Steering Committee for the Xarelto litigation in federal court in New Orleans.
To learn more about Ross Feller Casey visit http://www.rossfellercasey.com/
http://www.prnewswire.com/news-releases/ross-feller-casey-files-nations-first-xarelto-lawsuit-alleging-once-a-day-dosage-led-to-stroke-300156976.html

Return to headline | Return to top
Xarelto Lawsuit Update: New Wrongful Death Lawsuit Filed Against Xarelto Manufacturers

Oct 9, 2015 | GTN News

By Marc Goldich

October 09, 2015 – /PressAdvantage/ – BloodThinnerHelp.com reports today on one of the latest lawsuits filed in the Xarelto multidistrict litigation, or MDL. This new federal lawsuit was filed by the son of a deceased Georgia man who passed away from complications due to internal bleeding. The lawsuit was filed on March 20, 2015 against the manufacturers of Xarelto, Bayer AG and Janssen Pharmaceuticals, a subdivision of Johnson&Johnson. The son, a Tennessee resident, alleges in the lawsuit that his father died from an uncontrollable internal bleeding incident which he believes was caused by his father’s Xarelto usage. This case is filed in the Xarelto MDL in the United States District Court for the Eastern District of Louisiana and is filed under case number 2:15-cv-00886.
Lawsuit Alleges Manufacturers Had Knowledge of Xarelto’s Dangers:
The complaint details how the deceased was prescribed Xarelto in November 2012 to treat his atrial fibrillation, a heart condition. In March of 2013, the plaintiff’s father died because of an internal bleeding event. The complaint further outlines that the deceased’s death would not have happened if they were made aware of the true risks of Xarelto before he began to take the drug. The complaint states that if they were aware of the true dangers, they would have opted for a safer alternative.
The plaintiff alleges that the manufacturers of Xarelto deliberately concealed knowledge about the blood thinner, including that it could cause irreversible life threatening internal bleeding, that the manufacturers failed to warn patients and doctors about these dangers, and that they failed to equip the medical community with the knowledge on how to stabilize a patient who experiences an internal bleed and is taking Xarelto.
Xarelto was approved by the Food and Drug Administration, FDA, in 2011 for the treatment of atrial fibrillation, deep vein thrombosis, and to be used in patients who have recently undergone a hip or knee replacement surgery. After many users of Xarelto reported experiencing negative adverse events while taking the drug, such as brain bleeds, gastrointestinal bleeds, and blood clots, the FDA has issued several warnings regarding the usage of Xarelto including two black box warnings. Black box warnings are the strictest warnings that the FDA can attach to a drug short of recalling it, it means that there is a reasonable risk of harm associated with the drug in question.
Increasing Number of Xarelto Lawsuits Filed:
Patients who have been harmed by Xarelto began to file lawsuits against the manufacturers of the drug, all making similar claims as the plaintiff from Tennessee outlined in this post, that Xarelto causes severe uncontrollable internal bleeding and that the manufactures were aware of these dangers and released the drug to market anyway. A motion was made to consolidate these lawsuist into a federal multidistrict litigation, MDL, in December 2014 and the trials are scheduled to begin in early 2017.
“We strongly encourage anybody who feels that they have been harmed by Xarelto to contact us immediately.” Xarelto attorney Marc Goldich said, “We expect to see even more cases filed as this litigation continues and yours could be next.”
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
http://www.mygtn.tv/story/30223061/xarelto-lawsuit-update-new-wrongful-death-lawsuit-filed-against-xarelto-manufacturers

Return to headline | Return to top

Plaintiff Attorney Blogs

Son Blames Xarelto for Father’s Death, Seeks Punitive Damages

Oct 2, 2015 | The Legal Examiner

By Eric T. Chaffin

In December 2014, the U.S. Judicial Panel on Multidistrict Litigation (JPML) consolidated all federal Xarelto lawsuits into one court in the Eastern District of Louisiana before the Honorable Judge Fallon. Currently, about 400 cases are pending there.
One of the cases recently filed involves a plaintiff who claims the anticoagulant blood caused internal bleeding that led to the death of his father.Plaintiff Claims Xarelto Caused Wrongful Death
The plaintiff, a Georgia resident, is the son of the man who allegedly died because of his ingestion of Xarelto. He’s also the representative of the decedent’s estate. He has filed the Xarelto lawsuit against manufacturers Janssen Pharmaceuticals and parent company Johnson & Johnson, as well as against co-manufacturer Bayer AG.
According to the complaint, the decedent was first prescribed Xarelto in November 2012 for his atrial fibrillation. The FDA approved the drug in 2011 for the treatment of non-atrial fibrillation, to help patients reduce their risk of blood clots and stroke.
The decedent continued to take Xarelto for several months. On March 27, 2013, he suffered serious internal bleeding that led to his death. The plaintiff claims that had his father known about the risks associated with Xarelto, he never would have taken it.Manufacturers Misinformed Patients About Xarelto
The plaintiff also notes in his case that the defendants told patients in advertisements that they wouldn’t need regular blood monitoring when taking Xarelto, like patients normally do when taking warfarin, the leading anti-coagulant for decades. They also noted that there were no known dietary restrictions with Xarelto, like there are with warfarin.
Such advertisements made Xarelto look like a “one size fits all” drug, the plaintiff states, while failing to provide adequate warnings about the risks. The boxed warming on the drug, for example, did not address the increased risk for serious and fatal bleeding, despite early clinical trials showing that in comparison to warfarin, patients taking Xarelto experienced more gastrointestinal bleeds and needed more transfusions.Doctors Question Lack of Xarelto Bleeding Antidote
The plaintiff also points to a January/February 2013 ad in the WebMD magazine in which the defendants advertised Xarelto—an ad that resulted in a warning letter from the FDA. The administration stated that the ad was misleading because “it minimizes the risks associated with Xarelto and makes a misleading claim.”
He also references a 2012 Huffington Post article in which prominent cardiologists and other health care professionals questioned the use of Xarelto, noting that the drug had no antidote for a bleeding emergency, as warfarin does. Indeed, patients taking warfarin who experience excessive bleeding can be treated with vitamin K injections to encourage blood to clot again. There is no such treatment for patients taking Xarelto who end up in the same situation, making bleeding events much more serious and potentially deadly.Defendants Failed to Provide Adequate Warnings
As in other Xarelto lawsuits, this one highlights the fact that the manufacturers didn’t do enough to warn doctors and patient of the potential risks, particularly of the fact that there was no readily available antidote for Xarelto bleeding. “Defendants merely indicated that there was a risk for bleeding and side-stepped the important issue of reversing the effects of Xarelto should a bleed occur,” the plaintiff states in his complaint.
He brings claims for failure to warn, defective design, negligence, negligent design, negligent misrepresentation, breach of warranties, and fraud. He seeks both compensatory and punitive damages.
http://newyork.legalexaminer.com/fda-prescription-drugs/son-blames-xarelto-for-fathers-death-seeks-punitive-damages/

Return to headline | Return to top
Xarelto Bleeding Lawsuit Alleges Ohio Man Bled to Death

Oct 2, 2015 | Top Class Actions

By Ashley Vanover

The controversial blood thinning drug Xarelto has been named in yet another lawsuit – this time following the death of an Ohio resident who was prescribed the medication in July 2013.
Plaintiff Judy C., filing on behalf of her deceased spouse, commenced her Xarelto wrongful death lawsuit on Sept. 15 in Louisiana federal court, home of the ongoing Xarelto MDL to address the alleged widespread injuries caused by the new generation anticoagulant.
According to the Xarelto lawsuit, the decedent Jerry C. used Xarelto beginning in July 2013 through September 2013, and subsequently suffered fatal internal bleeding. Jerry ultimately died on Oct. 20, 2013, due to his injuries that were allegedly a direct result of using Xarelto
The Xarelto lawsuit further accuses the defendants of purposely concealing important safety information from the medical community, the U.S. Food and Drug Administration, and the public; the case also claims the pharmaceutical companies did not test the drug enough before it was put on the market.
Xarelto Side Effects
At the heart of the Judy’s Xarelto lawsuit are the allegations that the makers of Xarelto engaged in deceitful marketing practices and failed to disclose known Xarelto bleeding risks and side effects.
The drug Xarelto was approved by the Food and Drug Administration (FDA) in 2011 for the treatment of deep-vein thrombosis and similar clotting risks following knee or hip surgery. Its arrival to the market was initially well-received, as the drug was considered a more-convenient alternative to the long-standing anticoagulant known as warfarin.
Unlike warfarin, however, Xarelto’s aggressive marketing campaigns promised patients they could maintain an active lifestyle without diet restrictions or regular trips to the blood clinic.
What these advertisements failed to mention, according to the Xarelto lawsuit, was that the blood thinner could cause a sharp increase in bleeding risks. This new generation blood thinner has been named in several studies as a dangerous anticoagulant alternative that should be used only under close supervision.
Xarelto Lawsuits
Xarelto has been targeted with increasing scrutiny over the past several years, and its manufacturers are alleged to have unlawfully concealed the truth about its tendency to cause life-threatening hemorrhages and internal bleeding. Consequently, a Xarelto multidistrict litigation was formed to help consolidate the growing number of cases against the makers of Xarelto.
The Xarelto lawsuit is seeking compensatory, economic, and punitive damages for Bayer and Janssen Pharmaceutical’s alleged deceptive and reckless practices in misrepresenting and omitting numerous facts about the dangers of taking Xarelto and causing the death of Jerry in part by their gross negligence. The filed complaint indicates a demand for a jury trial for this case.
The Xarelto Lawsuit is Case No. 2:15-cv-04424, in the U.S. District Court for the Eastern District of Louisiana.
It is part of the Xarelto MDL known as In re: Xarelto (Rivaroxaban) Products Liability Litigation, MDL 2592, in the U.S. District Court for the Eastern District of Louisiana.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/173532-xarelto-bleeding-lawsuit-alleges-ohio-man-bled-to-death/

Return to headline | Return to top
Bellwether Trials Scheduled for Xarelto Coordinated Litigation

Oct 2, 2015 | Drug Reporter

By Whitney Taylor

Four bellwether trials have been scheduled in the ongoing coordinated proceedings underway involving the blood-thinning medication Xarelto. The judge overseeing the coordination has put four trials on the calendar in the first half of 2017, which will provide valuable insight into how subsequentXarelto lawsuits may be resolved.
All of the cases included in the coordination include allegations of serious bleeding injuries related to Xarelto.
Coordination of Xarelto lawsuits
Xarelto multidistrict litigation has been in progress since December 2014. The MDL was established to streamline the early trial proceedings for a growing number of similar lawsuits involving Xarelto. Currently, there are nearly 1,700 cases regardinguncontrollable bleeding in Xarelto users. Some of those bleeding events have been fatal.
The judge overseeing the Xarelto MDL, U.S. District Judge Eldon Fallon, issued a case management order on September 15, listing the dates of the early trials. The first bellwether trial is scheduled to begin on February 6, 2017, followed by a second trial on March 13, 2017. A third trial, slated for April 24, will be held in Mississippi, while the fourth, beginning on May 30, will take place in Texas. U.S. District Courts for the last two bellwether trials have yet to be determined. Locations are also subject to change, based on the discretion of the court, the case management order states.
The cases that will go before these juries will be selected from a pool of 40 cases. The selection process has also been outlined in the recent order, with specific dates set to complete various stages of the process. The first 40 cases will be determined by January 11, 2016, with the plaintiff choosing 10, the defendant choosing 10 and the remaining 20 selected randomly. The final selection of bellwether trials is slated to be completed by August 1, 2016.
History of Xarelto side effects
Xarelto was introduced to the U.S. market in 2011, and was highly touted by its manufacturer Bayer as a safe and effective alternative to the older blood-thinning medication warfarin. Unlike warfarin, Xarelto and its predecessor Pradaxa did not require regular blood monitoring or dietary restrictions. The drugs were approved to treat patients with certain types of atrial fibrillation to reduce their risk of blood clots and stroke.
However, another difference was discovered once the drugs were on the market that raised significant concern. Unlike warfarin, Xarelto and Pradaxa had no antidote in the event of an unexpected bleeding event. This led to uncontrollable bleeding that required emergency medical treatment and resulted in the death of some patients.
In 2012, the Huffington Post reported on a growing number of adverse events involving Pradaxa that were concerning members of the medical community. Concerns about Xarelto soon followed, as the drug that was introduced a year after Pradaxa began to show similar risks. Patients injured by the drugs began filing lawsuits against the manufacturers, claiming companies failed to properly warn patients and the medical community about the dangers associated with their products.
http://drugreporter.com/2015/10/bellwether-trials-scheduled-xarelto-coordinated-litigation/

Return to headline | Return to top
The Truth About The Blood Thinner And The Side Effects Of Xarelto

Oct 3, 2015 | Xarelto Settlement Lawyers

Have you taken Xarelto and now you are wondering if you have suffered any side effects from it? Maybe you are wondering what the side effects of Xarelto are. If you are curious about the side effects of xarelto , then continue to read the rest of this article, as some of the side effects will be discussed below.
1. Common Side Effects-
There are quite a few common side effects associated with Xarelto, and this includes pain in the back, bleeding gums, as well as blood in your stool. The pain in your back could vary in pain, and so can the amount of blood in your stool. Asides from those three side effects, other common ones include bowel or bladder dysfunction, as well as tingling feelings or the feeling of pins and needles. You might also experience some itching or burning.
Those who cough off blood or have a hard time breathing or swallowing may be doing so because of using Xarelto. The drug can also cause you to have a headache and you might feel dizzy, as this is another side effect associated with the drug. Another common side effect that some users may experience is weakness in one or both of their legs.
Nosebleeds, prolonged bleeding from cuts and numbness are other common side effects associated with Xarelto. Not only that, but other common ones include stools that are tarry and are red or black. If your urine is red or dark brown, then it may be because you are using Xarelto, and if you are a woman, then you may experience an increased menstrual flow.
There are even more common side effects that the drug has. One of the most serious and common ones is throwing up blood. Sometimes you might vomit material that resembles coffee grounds, and you might experience paralysis.
2. Less Common Side Effects-
Xarelto can cause less common side effects, which includes fainting. Not everyone will experience this side effect, but some people may. Feeling pain in your arms or legs, as well as wound secretion are other less common side effects of xarelto.
3. Rare Side Effects-
Asides from the common and less common side effects, there are a few rare ones that some users may encounter. One of the most rarest ones is burning while urinating. As for how much it will burn, that depends, but generally speaking, a burning sensation may be felt by some users of Xarelto
Another rare one is having a very hard time urinating. You may feel like you have to urinate, but you may find it difficult to do. Asides from being difficult, you might even find it painful to urinate.
If you experience those side effects, and you are taking Xarelto, then you should contact your doctor. The side effects may be the result of using the drug. Even if they are not, it is still a good idea to have a doctor look at you.
4. Unknown Side Effects-
There are some side effects of xarelto which are not really familiar, therefore it is not really proven that some unknown incidents are a result of using Xarelto. With that said, it is possible that some other side effects associated with Xarelto are pain in the stomach region, as well as swelling and your vision may become blurred or your skin could blister up or peel. Very dark urine is another potential side effect, but unproven one.
There are two more side effects that could potentially be linked to Xarelto and this includes blisters. If you take the drug and notice that blisters have appeared, then this may very well be because of Xarelto. Muscle spasms may also be experienced by Xarelto users, and if you do experience such symptoms, then you might want to consider getting medical attention because it may or may not be the results of using Xarelto.
As you can see, there are a lot of different side effects of Xarelto. If you suspect that you have suffered from any of the above side effects, then you should visit your doctor as soon as possible. They will be able to examine you, speak with you and determine whether or not Xarelto resulted in side effects.
http://xarelto-settlement.com/the-truth-about-the-blood-thinner-and-the-side-effects-of-xarelto/

Return to headline | Return to top
So What is the Xarelto Lawsuit About?

Oct 4, 2015 | Legal Guardianship

They say taking street drugs can kill you. Well, that is obviously true. You see it in the news every single day. However, another news story that is becoming quite popular is prescription drugs causing serious harm and in some cases killing people. It is not the thing you would expect to happen when your doctor writes you a prescription to treat something you might be suffering from or at risk for. The Xarelto lawsuitis an example. It is alleged that the drug is responsible for causing major bleeding events in some people who take it. The drug is intended to save lives. It is supposed to stop dangerous blood clots that can cause strokes from forming.
However, some people have reported serious internal bleeding events that they associate with taking Xarelto. There is a risk of bleeding with all drugs in this class. So, what is the Xarelto lawsuit about? If the label warns that serious bleeding can occur, then one might wonder how you can have a leg to stand on going up against the drug manufacturer. The claim is that the drug’s benefits over the standard treatment of warfarin are overstated. If the claims were valid, then the associated risks might be worth it. An exacerbating factor is that there is no counter drug to available to reverse the effects of Xarelto based on how it works. For warfarin, a dose of Vitamin K counteracts the effects of its blood thinning capability.
You might now think that if people overdosed on Xarelto then it is their own fault. however, it is common for blood tests to come back showing that warfarin levels are too high or even too low. If it got dangerously high, then some Vitamin K could be administered. For Xarelto building up in a patient to unsafe levels, there is nothing to counteract its effects. So, people that have been harmed are more likely to be eligible for compensation because them or their doctor may be more inclined to use the drug based on invalid claims, and that there is no counteracting agent if levels get too high.
http://www.eugad.eu/so-what-is-the-xarelto-lawsuit-about/

Return to headline | Return to top
Doctors Waiting On Real-World Safety Data From New Blood Thinners

Oct 4, 2015 | Righting Injustice

By Jennifer Walker-Journey

Drugs from a new class of blood thinners are gaining traction in sales, but analysts say they have a lot to prove before doctors push aside the long-used warfarin for the new drugs.
The new blood thinners are from a class known as factor Xa inhibitorsand include the brand names Pradaxa, Xarelto and Eliquis. They have been approved sometime within the past five years and are used to prevent strokes caused by blood clots in patients with a common heart rhythm abnormality called atrial fibrillation. Xarelto and Eliquis are also used to treat and prevent blood clots in various patients including those who have recently undergone hip or knee replacement surgeries.
Laksmi Dharmarajan, an analyst with the research and consulting firm GlobalData, says doctors are waiting on real-world safety data before they switch patients from warfarin to one of the newer blood thinners. “Most physicians are reluctant to take responsibility for possible complications, such as gastrointestinal bleeding, that may arise from using higher doses,” Dharmarajan said. “As a result, there is a tendency among health care providers to resort to using warfarin for high-risk patients even though it does not perform very well in these cases.”
Warfarin, which has been on the market for more than 50 years, does carry bleeding risks. So do the newer anticoagulants, Pradaxa, Xarelto and Eliquis. These risks include gastrointestinal bleeds as well as brain hemorrhaging and bleeding deaths.
However, what warfarin offers that the factor Xa inhibitors do not is an antidote that can reverse the bleeding effects of the drug in the event of a bleeding emergency. No approved reversal agents are currently available for Pradaxa, Xarelto or Eliquis.
Last year, Boehringer Ingelheim paid $650 million to settle lawsuits alleging the company did not adequately warn patients about bleeding risks with Pradaxa. Bayer and Johnson & Johnson’s Janssen Pharmaceuticalscurrently face similar lawsuits with Xarelto, as are Pfizer and Bristol-Myers Squibb with Eliquis.
http://www.rightinginjustice.com/news/2015/10/04/doctors-waiting-on-real-world-safety-data-from-new-blood-thinners/

Return to headline | Return to top
Xarelto and the FDA: An Uneasy Relationship

Oct 3, 2015 | Baron and Budd

Since the U.S. Food and Drug Administration (FDA) first approved Xarelto for use in 2011 after hip or knee surgeries, the drug has been placed under intense scrutiny by the agency. Even though the FDA granted approval for the medication to prevent pulmonary embolism (blood clots in the lung) and deep vein thrombosis after hip and knee procedures, the agency had serious concerns about the protocols used in conducting certain clinical studies. Over the years, the FDA has had some reservations regarding Xarelto. Here are a few examples.
2014
The FDA required new language be added to Xarelto labeling in regard to warnings and precautions. This new verbiage notified doctors, caregivers and patients about possibly dangerous side effects and risks associated with the drug. For example, a warning was added informing patients of the risks of using Xarelto after receiving epidural anesthesia for a spinal procedure. There was also a warning added about the lack of an antidote should excessive bleeding occur in a patient taking the drug.
2013
The agency sent a letter to Johnson & Johnson (the parent company of Xarelto manufacturer Janssen Pharmaceuticals) informing the company that its advertising was misleading. According to the agency, the ads, which occurred in WebMD magazine, downplayed the potential risks of taking the drug. It also found that the ad mistakenly claimed that Xarelto needed no dosage adjustments.
2012
The FDA’s Cardiovascular and Renal Drugs Advisory Committee met to discuss whether the uses of Xarelto should be extended. The committee could not agree on whether to grant the new uses or to wait for further information; some of the members said the evidence presented by Johnson & Johnson was unreliable. It eventually voted 6-4 against allowing these uses. However, the FDA ultimately allowed some expansion in November of that year.
https://baronandbudd.com/protecting-whats-right/2015/10/xarelto-fda/

Return to headline | Return to top
Xarelto Uncontrollable Bleeding Trials Set for 2017

Oct 5, 2015 | The Legal Examiner

By Shezad Malik MD JD

Since December 2014, all federal product liability lawsuits filed against Bayer and Johnson & Johnson over the bleeding side effects of Xarelto have been centralized and consolidated before U.S. District Judge Eldon Fallon in the Eastern District of Louisiana as part of an MDL, or multidistrict litigation.
4 Xarelto Bellwether Trials Set
Judge Fallon set a series of four bellwether trials to go before juries in the Spring of 2017. As of September 15, according the data provided by the Judicial Panel Multidistrict Litigation (JPML) there are 1,710 Xarelto injury lawsuits in the Eastern District of Louisiana.
The number of Xarelto lawsuits continue to be filed by individuals across the United States, alleging severe and deadly bleeding complications.
Bellwether Trials in Louisiana, Mississippi and Texas
The first two trials will be held in the Eastern District of Louisiana, on February 6 and March 13, 2017. The third trial will be held in Mississippi on April 24, 2017 and the fourth trial will be held in Texas on May 30, 2017.
According to Judge Fallon’s order, the cases that will go before juries on these dates will be pulled from a pool of 40 lawsuits to be selected in January 2016. These cases will be trial ready, with case-specific discovery, including depositions of plaintiffs, prescribing doctors, treating physicians and sales representatives of the drug makers.
What is Xarelto?
Xarelto (rivaroxoaban) was released and approved for sale in 2011 as a superior replacement for Coumadin (warfarin). Xarelto is used to reduce the risk of blood clots among patients at risk for deep vein thrombosis, pulmonary embolism and those patients at risk for a stroke with atrial fibrillation.
Atrial fibrillation is a common heart rhythm problem, which leads to embolic strokes, from blood clots that develop in the heart and travel up to the brain.
Xarelto has the largest share of the market for anticoagulants and is considered a blockbuster drug, with annual sales over $1 Billion in the United States.
Anticoagulant Bleeding Risks: No Xarelto Antidote
All anticoagulants or blood thinners have a risk of bleeding and injury, but Xarelto has been linked to a significant number of injuries involving catastrophic and uncontrollable bleeds, including death.
Xarelto has been advertised heavily as being easier to use than warfarin, since it does not require regular blood monitoring. According to several recent studies, those claims may be in doubt. Medical researchers have indicated that Xarelto blood monitoring may actually help doctors identify patients at the greatest risk of bleeding.
Plaintiffs are filing bleeding lawsuits claiming that the drug manufacturers suppressed information about the lack of a reversal agent. Warfarin’s blooding thinning effects can be quickly reversed in an emergency, there is no antidote for Xarelto.
Similar Lawsuits Claims For Pradaxa
Pradaxa, is another new-generation anticoagulant introduced by Boehringer Ingelheim in October 2010. In 2014, there were 3,592 serious adverse event reports involving Pradaxa, with 752 involving the death of the patient, compared with 3,331 reports associated to Xarelto bleeding problems, with 379 involving a patient death.
Similar allegations of a lack of an antidote, were raised in more than 4,000 Pradaxa lawsuits. On the eve of trial, Boehringer Ingelheim agreed to pay $650 million in Pradaxa settlements, with an average of about $150,000 per claim.
http://fortworth.legalexaminer.com/fda-prescription-drugs/xarelto-uncontrollable-bleeding-trials-set-for-2017/

Return to headline | Return to top
Xarelto Side Effects Lawsuit Filed for Wrongful Death

Oct 5, 2015 | American Injury Attorney Group

A Xarelto side effects lawsuit has been filed by a man who alleges that the blood thinner caused the wrongful death of his father. The lawsuit was filed two years after the plaintiff’s father died from a major internal bleed, Xarelto lawyersnote.
If you or a loved one took Xarelto and suffered complications, contact the American Injury Attorney Group today to learn more about your options. We can answer your questions in a free, confidential, no-obligation consultation, and if you wish to pursue a claim, we can connect you with an affiliated Xarelto lawsuit attorney.
Important: The time you have to pursue a claim is limited. Contact us for more information.
Plaintiff Claims Insufficient Safety Testing
Xarelto is a commonly used blood thinner that treats and prevents blood clots and also lowers the risk of stroke in patients who have atrial fibrillation. The lawsuit, filed on March 2015, alleges that the plaintiff’s father was prescribed Xarelto by his doctor for the treatment of atrial fibrillation. After taking the drug for five months the plaintiff’s father suffered an internal bleed and died.
The plaintiff not only claims that the drug makers, Bayer AG and Janssen Pharmaceuticals, were negligent in failing to perform sufficient testing on the drug, but his lawsuit also alleges that the companies acted negligently by failing to warn the public of the dangerous side effects associated with Xarelto. The drug has been linked to serious injury and death as a result of uncontrollable internal bleeding.
Injured Patients May Be Entitled to Compensation
If a drug maker fails to fulfill its duty to provide safe drugs and to warn of potentially harmful side effects that may be associated with its medication, it could be held liable for any injuries that may result. Patients who have been injured by Xarelto may be entitled to compensation for damages, including:
Medical expenses
Pain, suffering, and mental anguish
Loss of income or ability to work
If a patient dies from complications after taking Xarelto, his or her family members may be able to pursue claims for their loved one’s wrongful death. Compensation may include:
Pain, suffering, and mental anguish from the loss of a loved one
Loss of financial support of a loved one
Funeral expenses
Affected patients are encouraged to speak with a Xarelto lawsuit attorney to learn more about their rights and remedies.
Contact Us For More Information
If you or a loved one took Xarelto and suffered complications, including internal bleeding, contact the American Injury Attorney Group for more information. You can fill out the form on this page, call us at the number listed at the top of the page, or email us at info@attorneygroup.com.
When you contact us, an attorney will follow up with you to speak with you about your case or answer questions that you might have. There is no cost or obligation to speak with us, and any information you provide will be kept confidential.
Please note that the law limits the time you have to pursue a claim for an injury. If you think you have a case, you should not delay taking action.
See our Frequently Asked Questions page for more information, and contact the American Injury Attorney Group today.
https://attorneygroup.com/blog/xarelto-side-effects-lawsuit/

Return to headline | Return to top
Ohio Woman Files Xarelto Gastro-Intestinal Bleeding Injury Lawsuit

Oct 6, 2015 | The Legal Examiner

By Shezad Malik MD JD

Molly Harr, from Ohio, has filed a personal injury and product liability lawsuit claiming that Xarelto side effects caused her to develop gastrointestinal bleeding, after using the oral blood thinner or anticoagulant for chronic atrial fibrillation.
Atrial fibrillation is a very common heart rhythm problem, which can cause strokes. The lawsuit was filed in the U.S. District Court for the Southern District of Ohio.
Plaintiff Allegations
Harr notes that she was prescribed Xarelto in September 2013, for treatment of atrial fibrillation. Within 2 months, she developed severe gastrointestinal bleeding, which have caused her health problems.
Since December 2014, all federal product liability lawsuits filed against Bayer and Johnson & Johnson over the bleeding side effects of Xarelto have been centralized and consolidated before U.S. District Judge Eldon Fallon in the Eastern District of Louisiana as part of an MDL, or multidistrict litigation.
4 Xarelto Bellwether Trials Set
Judge Fallon set a series of four bellwether trials to go before juries in the Spring of 2017. As of September 15, according the data provided by the Judicial Panel Multidistrict Litigation (JPML) there are 1,710 Xarelto injury lawsuits in the Eastern District of Louisiana.
The number of Xarelto lawsuits continue to be filed by individuals across the United States, alleging severe and deadly bleeding complications.
Bellwether Trials in Louisiana, Mississippi and Texas
The first two trials will be held in the Eastern District of Louisiana, on February 6 and March 13, 2017. The third trial will be held in Mississippi on April 24, 2017 and the fourth trial will be held in Texas on May 30, 2017.
According to Judge Fallon’s order, the cases that will go before juries on these dates will be pulled from a pool of 40 lawsuits to be selected in January 2016. These cases will be trial ready, with case-specific discovery, including depositions of plaintiffs, prescribing doctors, treating physicians and sales representatives of the drug makers.
What is Xarelto?
Xarelto (rivaroxoaban) was released and approved for sale in 2011 as a superior replacement for Coumadin (warfarin). Xarelto is used to reduce the risk of blood clots among patients at risk for deep vein thrombosis, pulmonary embolism and those patients at risk for a stroke with atrial fibrillation.
Atrial fibrillation is a common heart rhythm problem, which leads to embolic strokes, from blood clots that develop in the heart and travel up to the brain.
Xarelto has the largest share of the market for anticoagulants and is considered a blockbuster drug, with annual sales over $1 Billion in the United States.
Anticoagulant Bleeding Risks: No Xarelto Antidote
All anticoagulants or blood thinners have a risk of bleeding and injury, but Xarelto has been linked to a significant number of injuries involving catastrophic and uncontrollable bleeds, including death.
Xarelto has been advertised heavily as being easier to use than warfarin, since it does not require regular blood monitoring. According to several recent studies, those claims may be in doubt. Medical researchers have indicated that Xarelto blood monitoring may actually help doctors identify patients at the greatest risk of bleeding.
Plaintiffs are filing bleeding lawsuits claiming that the drug manufacturers suppressed information about the lack of a reversal agent. Warfarin’s blooding thinning effects can be quickly reversed in an emergency, there is no antidote for Xarelto.
Similar Lawsuits Claims Settled For Pradaxa
Pradaxa, is another new-generation anticoagulant introduced by Boehringer Ingelheim in October 2010. In 2014, there were 3,592 serious adverse event reports involving Pradaxa, with 752 involving the death of the patient, compared with 3,331 reports associated to Xarelto bleeding problems, with 379 involving a patient death.
Similar allegations of a lack of an antidote, were raised in more than 4,000 Pradaxa lawsuits. On the eve of trial, Boehringer Ingelheim agreed to pay $650 million in Pradaxa settlements, with an average of about $150,000 per claim.
http://fortworth.legalexaminer.com/fda-prescription-drugs/ohio-woman-files-xarelto-gastro-intestinal-bleeding-injury-lawsuit/

Return to headline | Return to top
Four Plaintiffs File Joint Complaint in Xarelto MDL

Oct 6, 2015 | Injury Lawyer News

By Sarah May

Adding to the growing list of lawsuits in the Xarelto federal multidistrict litigation (MDL), a group of four plaintiffs have come together to file a joint complaint alleging that they each suffered serious harm after using Jannsen’s anticoagulant drug. The highly detailed complaint outlines the history of Xarelto, how it came to market and the reasons why plaintiffs believe its manufacturer negligently placed the general public at serious, unnecessary risk of severe complications such as those they experienced.
Four plaintiffs in Xarelto joint complaint
The four plaintiffs in this Xarelto lawsuit each claim to have suffered distinct and very serious harm after having taken the blood-thinning drug as prescribed by their physician.
Kentucky resident Sharon K. Bradshaw took Xarelto from July of 2014 through August of the same year and suffered a stroke on August 12, 2014. Indiana plaintiff Thomas Homco used Xarelto from August 7, 2013 through August 27, 2013, the date on which he suffered a serious gastrointestinal bleedingevent. Plaintiff Bertha P. Valk of Jackson County, Oregon ingested Xarelto from March of 2012 through September 2013, the month in which she experienced a gastrointestinal bleed. Plaintiff Melba Wiechbrodt of Oklahoma took Xarelto for approximately one month in the fall of 2012, ultimately suffering a thalamic hemorrhage on October 12 of that year. The incident proved fatal on October 13, and this lawsuit has been joined by her estate’s representative.
Allegations of negligence against Jannsen, Bayer
The complaint in this case alleges numerous acts of negligence on the part of drug makers Jannsen and Bayer as they sought to bring Xarelto to the American market. Specifically, the complaint cites serious irregularities in the studies used in support of the firms’ bid for FDA approval of the drug for the prevention of deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgeries.
The so-called “RECORD” studies purportedly indicated that Xarelto was a superior drug to those already existing on the marketplace, though the FDA itself had found rampant protocol violations during the study, including “systemic discarding of medical records,” unauthorized unblinding, falsification and improprieties in randomization.
Even with these facts, the defendants received approval for Xarelto as an aid in reducing the risk of stroke and embolism in patients with non-valvular atrial fibrillation, largely as a result of the so-called “ROCKET AF” study. This study argued that Xarelto was superior to existing blood thinner warfarin, though well-known flaws in this study drew the attention of the FDA as well as advocacy group Public Citizen. Further, the “once daily” dosing recommendations for the drug were assailed as being chosen more for marketing purposes than for reasons of drug efficacy.
The complaint alleges that the use of Xarelto without appropriate blood monitoring, dose adjustment and twice a day dosing can result in major, life-threatening bleeding events, information that was essentially disregarded by the makers of the drug.
Multiple claims for relief included in Xarelto lawsuit
The plaintiffs in this case allege that Janssen and Bayer engaged in numerous acts of negligence with regard to placing Xarelto on the U.S. market, and have included a series of distinct counts in their claims for relief. Among them are:
Strict liability
Defective manufacturing
Defective design
Failure to warn of known risks
Breach of express and implied warranties
Negligent misrepresentation
Fraud
Violation of consumer protection laws
As a result of the foregoing, the plaintiffs in this case are seeking compensatory damages including, but not limited to, pain, suffering, loss of enjoyment, emotional distress and other non-economic damages; economic damages in the form of medical expenses and lost earnings; attorney fees and costs and punitive damages “in an amount sufficient to punish defendants and deter future similar conduct.”
http://injurylawyer-news.com/2015/10/four-plaintiffs-file-joint-complaint-xarelto-mdl/

Return to headline | Return to top
Xarelto Lawsuit Update: Recent Lawsuit Filed By New York Plaintiff

Oct 7, 2015 | The Legal Herald

By Marc Goldich

Federal internal bleeding lawsuits are filed against the manufacturers of Xarelto, alleging the drug can cause serious, uncontrollable internal bleeding. A Texas woman has recently filed a lawsuit in New York state against the manufacturers of the anticoagulant drug Xarelto, Bayer AG and Janssen Pharmaceuticals, a subdivision of Johnson&Johnson.
The lawsuit is filed in federal court for the Eastern District of New York and is listed under federal court docket number 1:14-CV-04524. It is alleging that the manufacturer's failure to adequately warn patients and doctors about the dangers of the drug and failure to perform sufficient safety testing on the blood thinner led to her serious injuries.
In this case, the plaintiff began to take Xarelto after her doctor prescribed it to her to prevent blood clots that could develop from her heart condition, atrial fibrillation. She took the blood thinner regularly for five months until she suffered from a very serious life threatening internal bleeding event. The internal bleed left her with a serious injury. The complaint filed did not go into specifics about the exact nature of the injuries she suffered, but it did state that the injuries suffered as a result of the uncontrollable, internal bleeding are permanent and require long term, future care.
Increasing Number of Xarelto Lawsuits Filed
The lawsuit filed in New York is just one of the many that have recently been filed against the manufacturers of Xarelto. These lawsuits filed all make similar allegations that the Texas woman makes, that Xarelto can cause severe, uncontrollable internal bleeding and that the manufacturers failed to adequately warn patients and doctors about the true dangers of the drug.
Xarelto is more dangerous than other blood thinners available on the market because there is currently no available antidote for the anticoagulant effects of the drug. Xarelto is a part of a new class of blood thinners known as Xa inhibitors. Xa inhibitors prevent clots by blocking the chemical in the blood that is responsible for making blood clot, thrombin. By blocking thrombin, Xarelto completely takes away the blood's ability to clot. In the case of more traditional blood thinners, such as Warfarin, if a patient suffers from an internal bleeding event while taking the drug, a doctor can administer vitamin K to reverse the effects of Warfarin and make the blood clot again. In contrast, if a patient is taking Xarelto, the drug is active in their system, and they suffer from an internal bleeding emergency, there is no medical way, short of extreme life-saving measures, to make the blood clot and stop the bleed.
As of December 2014, the federally filed lawsuits against the manufacturers of Xarelto have been consolidated into a federal multidistrict litigation in the United States District Court for the Eastern District of Louisiana.
"If you or a loved one have suffered from an injury after taking Xarelto, contact us immediately." Xarelto attorney Marc Goldich said, "You may be entitled to significant compensation for your pain and suffering."
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
http://legalherald.com/xarelto-lawsuit-update-recent-lawsuit-filed-by-new-york-plaintiff/

Return to headline | Return to top
Xarelto Gastrointestinal Bleeding Followed Use for Atrial Fibrillation, Lawsuit Alleges

Oct 8, 2015 | AboutLawsuits.com

By Irvin Jackson

An Ohio woman has filed a product liability lawsuit alleging that side effects of Xarelto caused her to suffer gastrointestinal bleeding and other problems, after using the novel oral anticoagulant for chronic atrial fibrillation.
The complaint (PDF) was brought in the U.S. District Court for the Southern District of Ohio on October 5, on behalf of Molly Ann Harr and her husband, Daniel Harr, Jr.
Harr indicates that she was prescribed Xarelto in September 2013, for treatment of atrial fibrillation. Just two months later, she experienced severe gastrointestinal bleeding, and subsequently anemia, which have left her with on-going health problems.
The case joins hundreds of similar Xarelto bleeding lawsuits filed throughout the federal court system, which each allege that the manufacturers of the new-generation anti-coagulant failed to adequately warn consumers and the medical community about the risks associated with the medication and the lack of an approved reversal agent to help control bleeding problems that may develop among users.
Harr indicates that she narrowly avoided being one of the growing number of deaths linked to Xarelto, pointing out that there were at least 2,081 similar adverse events reported involving users of the drug in 2012, including 151 deaths. However, by the time she began using the medication in 2013, the Xarelto warning label still failed to adequately warn about the potential bleeding risk.
The lawsuit will be consolidated with about 1,700 claims pending in a federal multidistrict litigation (MDL), which is currently centralized for pretrial proceedings before U.S. District Judge Eldon Fallon in the Eastern District of Louisiana. However, if Xarelto settlements or another resolution for the litigation are not reached following discovery and a small number of bellwether trials, Harr’s complaint and other similar lawsuits may be remanded back to the U.S. District Courts where they were originally filed for separate trial dates.Xarelto Bleeding Problems
Xarelto (rivaroxoaban) was introduced in 2011 as a superior replacement for Coumadin (warfarin), designed to reduce the risk of blood clots among individuals at risk for deep vein thrombosis or pulmonary embolism. Since it hit the market, the drug has been aggressively marketed and has quickly grown to become one of the top selling medications in the United States.
While all blood thinners carry a risk of bleeding injury, Xarelto has been linked to a surprising number of problems involving severe and uncontrollable bleeds, sometimes resulting in death.
Xarelto has been promoted as easier to use than warfarin, since it does not require regular blood monitoring. However, several recent studies have raised questions about those claims, with researchers suggesting that Xarelto blood monitoring may actually help doctors identify patients at the greatest risk of bleeding.
In addition to failing to warn about the risk of bleeding and importance of blood monitoring, plaintiffs pursuing bleeding lawsuits over Xarelto allege that the drug makers withheld information about the lack of a reversal agent, which doctors could use to stop hemorrhaging that may develop among users.
While warfarin’s blooding thinning effects can be quickly reversed in an emergency, there is no antidote for Xarelto.
http://www.aboutlawsuits.com/xarelto-gastrointestinal-bleeding-atrial-fibrillation-lawsuit-88156/

Return to headline | Return to top
Xarelto Bellwether Trials Set

Oct 8, 2015 | Drug Lawsuit Source

In previous months, lawsuits against the Johnson & Johnson and Bayer AG’s popular blood thinner, Xarelto, have continued to rise dramatically. In response to the increasing number of plaintiffs bringing cases alleging injuries as the result of being prescribed and taking Xarelto, several bellwether trials have been scheduled to take place in the United States within the next year and a half to two years.
What is a Bellwether Trial?
Bellwether trials are intended to reduce redundancies and inconsistencies when there are several similar or nearly identical lawsuits against the same defendant or defendants. Instead of each case being tried individually, one or a few of the tens or hundreds of cases are selected as representative of the majority of the cases. These lawsuits are then tried in lieu of all of the cases with the hope that they will set a precedent for the remaining cases. Bellwether trials reduce the need for courts to designate significant resources for one type of lawsuit, and it also reduces the risk that different courts will find different verdicts in very similar or even nearly identical cases. In the pending Xarelto litigation, four bellwether trials have been scheduled already across the U.S. The first two bellwether trials have been set for February and March of 2017 in the Federal Court of the Eastern District of Louisiana. A third bellwether trial is scheduled for April of 2017 in Mississippi, and the fourth has been set for May of the same year in Texas.
Summary of Xarelto Litigation Allegations
The anticoagulant Xarelto has been approved by the United States Food and Drug Administration, but the FDA has followed up the approval with a warning regarding the risk of Xarelto patients bleeding out due to the lack of an antidote that has met all the requirements to be approved by the FDA. Fortunately, Portola Pharmaceuticals is in the process of undergoing testing for its promising drug Andexanet alfa which has shown positive results in offsetting the effects of Xarelto. Until this antidote is FDA-approved, Xarelto patients run the risk of bleeding out before the drug wears off naturally. Xarelto has also been linked to intestinal bleeding and eye hemorrhaging. As a result of these negative and potentially even fatal side effects, hundreds of lawsuits have been filed against Xarelto’s manufacturers. The lawsuits allege that the plaintiff suffered an injury as the result of taking Xarelto and that the manufacturers knew or should have known about the health risks associated with their drug but that they failed to warn the doctors and patients.
Our Xarelto Lawyers Can Help You
Our dangerous drug attorneys can help if you or someone you care about was harmed as a result of taking Xarelto. Lawsuits have been filed against the manufacturers by both patients and their families seeking compensation for injuries. You may be entitled to a settlement if you were harmed by Xarelto. We do not charge any legal fees unless you receive a settlement and we pay all of the case costs. If your claim is not successful for any reason, you do not owe us anything. We put it in all in writing for you. Our Xarelto lawyers will help you file your lawsuit.
Our No Fee Promise on Xarelto Cases
You can afford to have our great team of lawyers on your side. When you choose us, it literally costs nothing to get started. We promise you in writing:
No money to get started
We pay all case costs and expenses
No legal fees whatsoever unless you receive a settlement
Phone calls are always free.
Start Your Xarelto Claim
Our Xarelto lawyers will help you file your lawsuit. To get started, you can:
Submit the Free Case Review Box on this page, orCall (866) 280-4722 any time of day to tell us about your case.
We will listen to your story and answer your questions. If you have claim, we will start immediately.
WARNING: There are strict time deadlines for filing Xarelto lawsuit claims.
http://www.druglawsuitsource.com/xarelto-bellwether-trials-set/

Return to headline | Return to top
New Xarelto Lawsuits Filed in 2015

Oct 8, 2015 | Xarelto Problems

21 cases from 10 districts over the blood-thinning drug Xarelto were consolidated into a multidistrict litigation (“MDL”) for pretrial proceedings before Judge Fallon in New Orleans. Meanwhile, more Xarelto lawsuits continue to mount, with 86 suits pending, according to the Judicial Panel on Multidistrict Litigation’s January 15, 2015 monthlyreport. All contend that the anticoagulant manufactured and marketed to safely and effectively clot blood has failed to do so, causing uncontrolled, sometimes fatal, bleeding. Consolidating the initial 21 suits allows the court to more efficiently address the nearly identical claims that Xarelto’s manufacturers, Bayer Healthcare and Janssen Pharmaceuticals, did not properly communicate the risks associated with Xarelto, including the fact that there is no known bleeding antidote for the drug. As the bellwether trials near, more lawsuits are likely to join the 86 suits pending in the MDL.
http://xareltoproblems.com/new-xarelto-lawsuits-filed-2015/

Return to headline | Return to top
Is Xarelto Linked with an Increased Risk of Liver Injury?

Oct 8, 2015 | The Legal Examiner

By Kendra Goldhirsch

Health Canada has completed a safety review of Xarelto (rivaroxaban), a newer-generation anti-coagulant medication manufactured by Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson).
According to a Summary Safety Review released on August 26, 2015, the department investigated the medication after two studies showed Xarelto was linked to liver injury in 16 patients. They wanted to find out if the drug could increase risk of liver injury, but so far they don’t have a clear answer because some of the reports failed to contain complete information. Due to ongoing concerns, Health Canada has asked healthcare professionals and patients to report any liver injury that could be related to the ingestion of Xarelto.
The FDA approved Xarelto in 2011 to help reduce the risk of blood clots in patients going through hip and knee replacement surgery, and later to help reduce the risk of stroke in patients with non-valvular atrial fibrillation. The drug has been connected with an increased risk of gastrointestinal bleeding leading to hospitalization and sometimes death.
Two Studies Raise Red Flags About Xarelto Liver Injury
The two studies that alerted Health Canada to the possibility of a link between Xarelto and liver injury included the following:
1. 2014: Physicians reported in the journal JAMA Internal Medicine that two patients developed serious liver problems while taking rivaroxaban, including “massively elevated transaminase activity levels and hyperbilirubinemia.” Both recovered rapidly after they stopped taking the drug. The authors added that between 2008 and 2013, 42 cases of liver injury possibly related to the ingestion of rivaroxaban had been reported to the Swiss Agency of Therapeutic Products. They concluded that treatment with the drug could be associated with “severe, symptomatic liver injury.”
2. 2014: A second study published in the Journal Hepatology reported on 14 cases of liver injury associated with rivaroxaban. Researchers searched databases for comparable cases, and found “a considerable number of additional hepatic [liver related] adverse events where rivaroxaban was reported as a suspected cause.” The authors recommended additional studies to determine the risks of liver injury associated with the drug, and advised doctors to be on the lookout for symptoms of liver disease in patients who are taking rivaroxaban.
Concerns Remain As Investigation Continues
Health Canada noted that at the time of their investigation, the Canada Vigilance Program had received a total of 61 reports of liver-related harmful effects in patients taking Xarelto. Assessment of the cases did not reveal a clear cause-and-effect relationship, however, Health Canada pointed to the fact that some of the reports contained only partial information.
The department also reviewed international data from the World Health Organization (WHO), and found 431 cases of liver injury in patients taking Xarelto, with 23 of these patients taking “only” Xarelto, and no other medications.
http://newyork.legalexaminer.com/fda-prescription-drugs/is-xarelto-linked-with-an-increased-risk-of-liver-injury/

Return to headline | Return to top
Atrial Fibrillation Patient Files Xarelto Bleeding Lawsuit

Oct 9, 2015 | Top Class Actions

By Paul Tassin

An atrial fibrillation patient filed a Xarelto bleeding lawsuit, alleging the drug caused dangerous gastrointestinal bleeding.
Plaintiff Lloyd E. says he started taking Xarelto in May 2014 on his doctor’s advice as a treatment for atrial fibrillation and coronary artery disease. A few months later, he says, he developed an acute gastrointestinal bleed for which he had to be hospitalized.
Lloyd argues the bleeding was directly attributable to the Xarelto he took for his cardiovascular conditions. So he filed a lawsuit against Xarelto’s maker Janssen Pharmaceuticals, its parent company Johnson & Johnson, Bayer Corporation, and their related companies.
The lawsuit argues the companies failed to properly disclose the risks of Xarelto bleeding. If they had, he says, he never would have taken Xarelto.
Xarelto (rivaroxaban) is an anticoagulant medication that’s been on the market since earning FDA approval in July 2011. Xarelto is often used to prevent blood clots and strokes in patients with non-valvular atrial fibrillation.
Other approved uses of Xarelto include treatment of deep vein thrombosis and pulmonary embolism, prevention of both those conditions before they happen, and reducing the risk of blood clots and related complications in patients who recently had hip or knee replacement surgery.
The marketing for Xarelto touted it as an improvement over warfarin, which for years had been medicine’s go-to anticoagulant. Lloyd says the defendants’ marketed Xarelto as not requiring ongoing blood monitoring or dietary restrictions. However, Lloyd claims Xarelto is not actually safer than warfarin and may be only slightly easier to use and administer.
Lloyd argues the labeling for Xarelto should have included a warning about the risk of excessive bleeding. He cited the ROCKET AF clinical trial, in which patients taking Xarelto had more bleeding events and more need for blood transfusions.
A print advertisement for Xarelto in WebMD magazine earned the defendants some negative attention from the FDA. In a letter to the defendants, Lloyd says, the FDA said the advertisement understated the risks associated with Xarelto and incorrectly stated that no dosage adjustments were necessary, contrary to the language on the FDA-approved label.
The Xarelto lawsuit also cites hundreds reports of adverse events associated with Xarelto, including 72 cases in Germany that ended in death. He says that in 2012, the Institute for Safe Medication Practices “identified 356 reports of serious, disabling, or fatal injury in which rivaroxaban was the primary suspect drug.”
Lloyd says the defendants knew this information about Xarelto side effects but purposely concealed it from patients and doctors.
Lloyd is raising claims based on theories of failure to warn, design defect, negligence, misrepresentation, breach of warranty, and fraud. He seeks compensation for pain and suffering, past and future medical expenses, and past and future physical impairment.
Lloyd is also asking for an award of punitive damages, arguing that the defendants acted “willfully, intentionally, and with reckless disregard” for both Lloyd’s rights and those of the public.
Lloyd’s Xarelto lawsuit is Case No. 3:15-CV-00413in the U.S. District Court, in the Eastern District of Tennessee.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/178082-atrial-fibrillation-patient-files-xarelto-bleeding-lawsuit/

Return to headline | Return to top

Add recipients

Suggested